Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 7/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.52 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6225147 | 1.00 | CHRNB4 (0.52) | CHRNB4CHRNA3TACR1FAAHCHRNB2 | |
| SCHEMBL447282 | 0.88 | CHRNB4 (0.48) | CHRNB4CHRNA3FAAH | |
| SCHEMBL1264856 | 0.88 | CHRNB4 (0.48) | CHRNB4CHRNA3FAAH | |
| SCHEMBL446091 | 0.88 | CHRNB4 (0.48) | CHRNB4CHRNA3FAAH | |
| SCHEMBL4364278 | 0.85 | CHRNB4 (0.71) | CHRNB4CHRNA3FAAHCHRNB2CHRNB1 | |
| SCHEMBL450269 | 0.85 | CHRNB4 (0.71) | CHRNB4CHRNA3FAAHCHRNB2CHRNB1 | |
| SCHEMBL4967754 | 0.85 | CHRNB4 (0.71) | CHRNB4CHRNA3FAAHCHRNB2CHRNB1 | |
| SCHEMBL6224599 | 0.83 | CHRNB4 (0.43) | CHRNB4CHRNA3TACR1CHRNB2CHRNB1 | |
| SCHEMBL3147108 | 0.83 | CHRNB4 (0.43) | CHRNB4CHRNA3TACR1CHRNB2CHRNB1 | |
| SCHEMBL6215959 | 0.81 | CHRNB4 (0.42) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | CHRNB4 3877/4885CHRNA3 3546/4885TACR1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.